Demographic and Treatment Variables Influencing Outcome for Localized Paratesticular Rhabdomyosarcoma

Results From a Pooled Analysis of North American and European Cooperative Groups

David O Walterhouse, Donald A Barkauskas, David Hall, Andrea Ferrari, Gian Luca De Salvo, Ewa Koscielniak, Michael C G Stevens, Hélène Martelli, Guido Seitz, David A Rodeberg, Margarett Shnorhavorian, Roshni Dasgupta, John C Breneman, James R Anderson, Christophe Bergeron, Gianni Bisogno, William H Meyer, Douglas S Hawkins, Veronique Minard-Colin

Research output: Contribution to journalArticle

Abstract

PURPOSE: Treatment recommendations for localized paratesticular rhabdomyosarcoma (PT RMS) differ in North America and Europe. We conducted a pooled analysis to identify demographic features and treatment choices that affect outcome.

PATIENTS AND METHODS: We retrospectively analyzed the effect of nine demographic variables and four treatment choices on event-free survival (EFS) and overall survival (OS) from 12 studies conducted by five cooperative groups.

RESULTS: Eight hundred forty-two patients with localized PT RMS who enrolled from 1988 to 2013 were included. Patients age ≥ 10 years were more likely than younger patients to have tumors that were > 5 cm, enlarged nodes (N1), or pathologically involved nodes ( P ≤ .05 each). With a median follow-up of 7.5 years, Kaplan-Meier estimates for 5-year EFS and OS were 87.7% and 94.8%, respectively. Of demographic variables, cooperative group, era of enrollment, age category, tumor size, Intergroup Rhabdomyosarcoma Study group, and T stage affected EFS ( P ≤ .05 each). Surgical assessment of regional nodes, which was performed in 23.5% of patients-usually in those age ≥ 10 years or with suspicious or N1 nodes-was the only treatment variable associated with EFS by univariable and multivariable analyses ( P ≤ .05 each) in patients age ≥ 1 year. A variable selection procedure on a proportional hazards regression model selected era of enrollment, age, tumor size, and surgical assessment of regional nodes as significant ( P ≤ .05 each) in the EFS model, and era of enrollment, age, tumor size, and histology ( P ≤ .05 each) in the OS model.

CONCLUSION: Localized PT RMS has a favorable prognosis. Age ≥ 10 years at diagnosis and tumor size larger than 5 cm are unfavorable prognostic features. Surgical assessment of regional nodes is important in patients age ≥ 10 years and in those with N1 nodes as it affects EFS.

Original languageEnglish
Pages (from-to)JCO2018789388
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology
DOIs
Publication statusE-pub ahead of print - Oct 23 2018

Fingerprint

Rhabdomyosarcoma
Disease-Free Survival
Demography
Neoplasms
Survival
Therapeutics
Kaplan-Meier Estimate
North America
Proportional Hazards Models
Histology

Cite this

Demographic and Treatment Variables Influencing Outcome for Localized Paratesticular Rhabdomyosarcoma : Results From a Pooled Analysis of North American and European Cooperative Groups. / Walterhouse, David O; Barkauskas, Donald A; Hall, David; Ferrari, Andrea; De Salvo, Gian Luca; Koscielniak, Ewa; Stevens, Michael C G; Martelli, Hélène; Seitz, Guido; Rodeberg, David A; Shnorhavorian, Margarett; Dasgupta, Roshni; Breneman, John C; Anderson, James R; Bergeron, Christophe; Bisogno, Gianni; Meyer, William H; Hawkins, Douglas S; Minard-Colin, Veronique.

In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23.10.2018, p. JCO2018789388.

Research output: Contribution to journalArticle

Walterhouse, DO, Barkauskas, DA, Hall, D, Ferrari, A, De Salvo, GL, Koscielniak, E, Stevens, MCG, Martelli, H, Seitz, G, Rodeberg, DA, Shnorhavorian, M, Dasgupta, R, Breneman, JC, Anderson, JR, Bergeron, C, Bisogno, G, Meyer, WH, Hawkins, DS & Minard-Colin, V 2018, 'Demographic and Treatment Variables Influencing Outcome for Localized Paratesticular Rhabdomyosarcoma: Results From a Pooled Analysis of North American and European Cooperative Groups', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, pp. JCO2018789388. https://doi.org/10.1200/JCO.2018.78.9388
Walterhouse, David O ; Barkauskas, Donald A ; Hall, David ; Ferrari, Andrea ; De Salvo, Gian Luca ; Koscielniak, Ewa ; Stevens, Michael C G ; Martelli, Hélène ; Seitz, Guido ; Rodeberg, David A ; Shnorhavorian, Margarett ; Dasgupta, Roshni ; Breneman, John C ; Anderson, James R ; Bergeron, Christophe ; Bisogno, Gianni ; Meyer, William H ; Hawkins, Douglas S ; Minard-Colin, Veronique. / Demographic and Treatment Variables Influencing Outcome for Localized Paratesticular Rhabdomyosarcoma : Results From a Pooled Analysis of North American and European Cooperative Groups. In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 ; pp. JCO2018789388.
@article{332c25a5e60b486bba6d38bbd18144eb,
title = "Demographic and Treatment Variables Influencing Outcome for Localized Paratesticular Rhabdomyosarcoma: Results From a Pooled Analysis of North American and European Cooperative Groups",
abstract = "PURPOSE: Treatment recommendations for localized paratesticular rhabdomyosarcoma (PT RMS) differ in North America and Europe. We conducted a pooled analysis to identify demographic features and treatment choices that affect outcome.PATIENTS AND METHODS: We retrospectively analyzed the effect of nine demographic variables and four treatment choices on event-free survival (EFS) and overall survival (OS) from 12 studies conducted by five cooperative groups.RESULTS: Eight hundred forty-two patients with localized PT RMS who enrolled from 1988 to 2013 were included. Patients age ≥ 10 years were more likely than younger patients to have tumors that were > 5 cm, enlarged nodes (N1), or pathologically involved nodes ( P ≤ .05 each). With a median follow-up of 7.5 years, Kaplan-Meier estimates for 5-year EFS and OS were 87.7{\%} and 94.8{\%}, respectively. Of demographic variables, cooperative group, era of enrollment, age category, tumor size, Intergroup Rhabdomyosarcoma Study group, and T stage affected EFS ( P ≤ .05 each). Surgical assessment of regional nodes, which was performed in 23.5{\%} of patients-usually in those age ≥ 10 years or with suspicious or N1 nodes-was the only treatment variable associated with EFS by univariable and multivariable analyses ( P ≤ .05 each) in patients age ≥ 1 year. A variable selection procedure on a proportional hazards regression model selected era of enrollment, age, tumor size, and surgical assessment of regional nodes as significant ( P ≤ .05 each) in the EFS model, and era of enrollment, age, tumor size, and histology ( P ≤ .05 each) in the OS model.CONCLUSION: Localized PT RMS has a favorable prognosis. Age ≥ 10 years at diagnosis and tumor size larger than 5 cm are unfavorable prognostic features. Surgical assessment of regional nodes is important in patients age ≥ 10 years and in those with N1 nodes as it affects EFS.",
author = "Walterhouse, {David O} and Barkauskas, {Donald A} and David Hall and Andrea Ferrari and {De Salvo}, {Gian Luca} and Ewa Koscielniak and Stevens, {Michael C G} and H{\'e}l{\`e}ne Martelli and Guido Seitz and Rodeberg, {David A} and Margarett Shnorhavorian and Roshni Dasgupta and Breneman, {John C} and Anderson, {James R} and Christophe Bergeron and Gianni Bisogno and Meyer, {William H} and Hawkins, {Douglas S} and Veronique Minard-Colin",
year = "2018",
month = "10",
day = "23",
doi = "10.1200/JCO.2018.78.9388",
language = "English",
pages = "JCO2018789388",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",

}

TY - JOUR

T1 - Demographic and Treatment Variables Influencing Outcome for Localized Paratesticular Rhabdomyosarcoma

T2 - Results From a Pooled Analysis of North American and European Cooperative Groups

AU - Walterhouse, David O

AU - Barkauskas, Donald A

AU - Hall, David

AU - Ferrari, Andrea

AU - De Salvo, Gian Luca

AU - Koscielniak, Ewa

AU - Stevens, Michael C G

AU - Martelli, Hélène

AU - Seitz, Guido

AU - Rodeberg, David A

AU - Shnorhavorian, Margarett

AU - Dasgupta, Roshni

AU - Breneman, John C

AU - Anderson, James R

AU - Bergeron, Christophe

AU - Bisogno, Gianni

AU - Meyer, William H

AU - Hawkins, Douglas S

AU - Minard-Colin, Veronique

PY - 2018/10/23

Y1 - 2018/10/23

N2 - PURPOSE: Treatment recommendations for localized paratesticular rhabdomyosarcoma (PT RMS) differ in North America and Europe. We conducted a pooled analysis to identify demographic features and treatment choices that affect outcome.PATIENTS AND METHODS: We retrospectively analyzed the effect of nine demographic variables and four treatment choices on event-free survival (EFS) and overall survival (OS) from 12 studies conducted by five cooperative groups.RESULTS: Eight hundred forty-two patients with localized PT RMS who enrolled from 1988 to 2013 were included. Patients age ≥ 10 years were more likely than younger patients to have tumors that were > 5 cm, enlarged nodes (N1), or pathologically involved nodes ( P ≤ .05 each). With a median follow-up of 7.5 years, Kaplan-Meier estimates for 5-year EFS and OS were 87.7% and 94.8%, respectively. Of demographic variables, cooperative group, era of enrollment, age category, tumor size, Intergroup Rhabdomyosarcoma Study group, and T stage affected EFS ( P ≤ .05 each). Surgical assessment of regional nodes, which was performed in 23.5% of patients-usually in those age ≥ 10 years or with suspicious or N1 nodes-was the only treatment variable associated with EFS by univariable and multivariable analyses ( P ≤ .05 each) in patients age ≥ 1 year. A variable selection procedure on a proportional hazards regression model selected era of enrollment, age, tumor size, and surgical assessment of regional nodes as significant ( P ≤ .05 each) in the EFS model, and era of enrollment, age, tumor size, and histology ( P ≤ .05 each) in the OS model.CONCLUSION: Localized PT RMS has a favorable prognosis. Age ≥ 10 years at diagnosis and tumor size larger than 5 cm are unfavorable prognostic features. Surgical assessment of regional nodes is important in patients age ≥ 10 years and in those with N1 nodes as it affects EFS.

AB - PURPOSE: Treatment recommendations for localized paratesticular rhabdomyosarcoma (PT RMS) differ in North America and Europe. We conducted a pooled analysis to identify demographic features and treatment choices that affect outcome.PATIENTS AND METHODS: We retrospectively analyzed the effect of nine demographic variables and four treatment choices on event-free survival (EFS) and overall survival (OS) from 12 studies conducted by five cooperative groups.RESULTS: Eight hundred forty-two patients with localized PT RMS who enrolled from 1988 to 2013 were included. Patients age ≥ 10 years were more likely than younger patients to have tumors that were > 5 cm, enlarged nodes (N1), or pathologically involved nodes ( P ≤ .05 each). With a median follow-up of 7.5 years, Kaplan-Meier estimates for 5-year EFS and OS were 87.7% and 94.8%, respectively. Of demographic variables, cooperative group, era of enrollment, age category, tumor size, Intergroup Rhabdomyosarcoma Study group, and T stage affected EFS ( P ≤ .05 each). Surgical assessment of regional nodes, which was performed in 23.5% of patients-usually in those age ≥ 10 years or with suspicious or N1 nodes-was the only treatment variable associated with EFS by univariable and multivariable analyses ( P ≤ .05 each) in patients age ≥ 1 year. A variable selection procedure on a proportional hazards regression model selected era of enrollment, age, tumor size, and surgical assessment of regional nodes as significant ( P ≤ .05 each) in the EFS model, and era of enrollment, age, tumor size, and histology ( P ≤ .05 each) in the OS model.CONCLUSION: Localized PT RMS has a favorable prognosis. Age ≥ 10 years at diagnosis and tumor size larger than 5 cm are unfavorable prognostic features. Surgical assessment of regional nodes is important in patients age ≥ 10 years and in those with N1 nodes as it affects EFS.

U2 - 10.1200/JCO.2018.78.9388

DO - 10.1200/JCO.2018.78.9388

M3 - Article

SP - JCO2018789388

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

ER -